Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Preclinical imaging of mammary intraepithelial neoplasia with positron emission tomography.

Abbey CK, Borowsky AD, Gregg JP, Cardiff RD, Cherry SR.

J Mammary Gland Biol Neoplasia. 2006 Apr;11(2):137-49. Review.

PMID:
17091397
2.

In vivo positron-emission tomography imaging of progression and transformation in a mouse model of mammary neoplasia.

Abbey CK, Borowsky AD, McGoldrick ET, Gregg JP, Maglione JE, Cardiff RD, Cherry SR.

Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11438-43. Epub 2004 Jul 26.

3.

Detection of internal mammary lymph node metastasis with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with stage III breast cancer.

Seo MJ, Lee JJ, Kim HO, Chae SY, Park SH, Ryu JS, Ahn SH, Lee JW, Son BH, Gong GY, Moon DH.

Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):438-45. doi: 10.1007/s00259-013-2600-y. Epub 2013 Nov 6.

PMID:
24196918
4.

Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan?

Caglar M, Kupik O, Karabulut E, Høilund-Carlsen PF.

Rev Esp Med Nucl Imagen Mol. 2016 Jan-Feb;35(1):3-11. doi: 10.1016/j.remn.2015.08.006. Epub 2015 Oct 26.

5.

Variability of dynamic 18F-FDG-PET data in breast cancer xenografts.

Pitman KE, Rusten E, Kristian A, Malinen E.

Acta Oncol. 2015;54(9):1399-407. doi: 10.3109/0284186X.2015.1062140. Epub 2015 Jul 28.

PMID:
26217987
6.

Detection of precursor lesions of pancreatic adenocarcinoma in PET-CT in a genetically engineered mouse model of pancreatic cancer.

Fendrich V, Schneider R, Maitra A, Jacobsen ID, Opfermann T, Bartsch DK.

Neoplasia. 2011 Feb;13(2):180-6.

7.

Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer.

Aukema TS, Straver ME, Peeters MJ, Russell NS, Gilhuijs KG, Vogel WV, Rutgers EJ, Olmos RA.

Eur J Cancer. 2010 Dec;46(18):3205-10. doi: 10.1016/j.ejca.2010.07.034. Epub 2010 Aug 16.

PMID:
20719497
8.

Staging the axilla in breast cancer patients with ¹⁸F-FDG PET: how small are the metastases that we can detect with new generation clinical PET systems?

Bellevre D, Blanc Fournier C, Switsers O, Dugué AE, Levy C, Allouache D, Desmonts C, Crouet H, Guilloit JM, Grellard JM, Aide N.

Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1103-12. doi: 10.1007/s00259-014-2689-7. Epub 2014 Feb 22.

10.
11.

Preoperative FDG-PET for axillary metastases in patients with breast cancer.

Chung A, Liou D, Karlan S, Waxman A, Fujimoto K, Hagiike M, Phillips EH.

Arch Surg. 2006 Aug;141(8):783-8; discussion 788-9.

PMID:
16924086
12.

PET Imaging of Breast Cancer: Role in Patient Management.

Lebron L, Greenspan D, Pandit-Taskar N.

PET Clin. 2015 Apr;10(2):159-95. doi: 10.1016/j.cpet.2014.12.004. Review.

PMID:
25829085
13.

Metastatic brachial plexopathy from breast cancer detected by 18F-FDG PET/MRI.

Treglia G, Paone G, Ceriani L, Giovanella L.

Rev Esp Med Nucl Imagen Mol. 2014 Jan-Feb;33(1):54-5. doi: 10.1016/j.remn.2013.06.007. Epub 2013 Aug 12. No abstract available.

14.

Simultaneous fluorescence and positron emission tomography for in vivo imaging of small animals.

Zhang B, Liu S, Liu F, Zhang X, Xu Y, Luo J, Shan B, Bai J.

J Biomed Opt. 2011 Dec;16(12):120511. doi: 10.1117/1.3665438.

PMID:
22191913
15.

Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.

Chang HT, Hu C, Chiu YL, Peng NJ, Liu RS.

PLoS One. 2014 Dec 17;9(12):e115127. doi: 10.1371/journal.pone.0115127. eCollection 2014.

16.

Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer.

Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, Yamamoto M, Hama Y, Tamura K, Ishida J, Abe Y, Mochizuki H.

Jpn J Clin Oncol. 2008 Apr;38(4):250-8. doi: 10.1093/jjco/hyn019.

PMID:
18407934
17.

Mammary cancer bone metastasis follow-up using multimodal small-animal MR and PET imaging.

Doré-Savard L, Barrière DA, Midavaine É, Bélanger D, Beaudet N, Tremblay L, Beaudoin JF, Turcotte EE, Lecomte R, Lepage M, Sarret P.

J Nucl Med. 2013 Jun;54(6):944-52. doi: 10.2967/jnumed.112.114215. Epub 2013 Apr 17.

18.
19.

Accuracy of 18F-FDG PET/CT for primary tumor visualization and staging in T1 breast cancer.

Koolen BB, van der Leij F, Vogel WV, Rutgers EJ, Vrancken Peeters MJ, Elkhuizen PH, Valdés Olmos RA.

Acta Oncol. 2014 Jan;53(1):50-7. doi: 10.3109/0284186X.2013.783714. Epub 2013 May 14.

PMID:
23672678
20.

Molecular imaging using PET for breast cancer.

Kurihara H, Shimizu C, Miyakita Y, Yoshida M, Hamada A, Kanayama Y, Yonemori K, Hashimoto J, Tani H, Kodaira M, Yunokawa M, Yamamoto H, Watanabe Y, Fujiwara Y, Tamura K.

Breast Cancer. 2016 Jan;23(1):24-32. doi: 10.1007/s12282-015-0613-z. Epub 2015 Apr 28. Review.

PMID:
25917108

Supplemental Content

Support Center